NASDAQ:TORC - resTORbio Stock Price, Forecast & News

resTORbio trades on the NASDAQ under the ticker symbol "TORC."

resTORbio, Inc. (NASDAQ:TORC) posted its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.14. View resTORbio's Earnings History.

resTORbio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for resTORbio.

4 Wall Street analysts have issued twelve-month price objectives for resTORbio's shares. Their forecasts range from $3.00 to $28.00. On average, they anticipate resTORbio's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 886.9% from the stock's current price. View Analyst Price Targets for resTORbio.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for resTORbio.

Press coverage about TORC stock has trended negative on Monday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. resTORbio earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for resTORbio.

resTORbio saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,860,000 shares, an increase of 50.0% from the January 15th total of 1,240,000 shares. Based on an average daily volume of 2,060,000 shares, the short-interest ratio is currently 0.9 days. Currently, 6.7% of the company's stock are short sold. View resTORbio's Current Options Chain.

Some companies that are related to resTORbio include MediciNova (MNOV), Agile Therapeutics (AGRX), Theratechnologies (THERF), LifeVantage (LFVN), Abeona Therapeutics (ABEO), Theratechnologies (THTX), Affimed (AFMD), Cerecor (CERC), Arbutus Biopharma (ABUS), Athersys (ATHX), Nature's Sunshine Products (NATR), Five Prime Therapeutics (FPRX), TAIWAN LIPOSOME/S (TLC), Scpharmaceuticals (SCPH) and Fortress Biotech (FBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include Novavax (NVAX), Denali Therapeutics (DNLI), SCYNEXIS (SCYX), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Cytokinetics (CYTK) and Editas Medicine (EDIT).

(TORC) raised $86 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

resTORbio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include UBS Group AG (1.69%), Acadian Asset Management LLC (1.26%), State Street Corp (0.94%), Geode Capital Management LLC (0.92%), Ruffer LLP (0.82%) and Charles Schwab Investment Management Inc. (0.24%). Company insiders that own resTORbio stock include Chen Schor and Puretech Health Llc. View Institutional Ownership Trends for resTORbio.

TORC stock was sold by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for resTORbio.

TORC stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Acadian Asset Management LLC, Ruffer LLP, Geode Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Brave Asset Management Inc.. View Insider Buying and Selling for resTORbio.

Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TORC stock can currently be purchased for approximately $1.57.

resTORbio has a market capitalization of $57.23 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About resTORbio.

The official website for resTORbio is http://www.restorbio.com/.

resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528.